Paclitaxel

Generic Name
Paclitaxel
Brand Names
Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
Drug Type
Small Molecule
Chemical Formula
C47H51NO14
CAS Number
33069-62-4
Unique Ingredient Identifier
P88XT4IS4D
Background

Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication

Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions
Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
Associated Therapies
-
Clinical Trials
Related News

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

First Posted Date
2021-08-16
Last Posted Date
2024-10-21
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
604
Registration Number
NCT05007106
Locations
🇺🇸

Memorial Sloan Kettering - Bergen ( Site 1025), Montvale, New Jersey, United States

🇺🇸

Memorial Sloan Kettering - Monmouth ( Site 1022), Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering - Basking Ridge ( Site 1023), Basking Ridge, New Jersey, United States

and more 70 locations

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

First Posted Date
2021-08-12
Last Posted Date
2024-07-31
Lead Sponsor
ALX Oncology Inc.
Target Recruit Count
450
Registration Number
NCT05002127
Locations
🇺🇸

The Oncology Institute of Hope & Innovation, Anaheim, California, United States

🇺🇸

University of California Los Angeles, Los Angeles, California, United States

🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

and more 80 locations

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

First Posted Date
2021-08-04
Last Posted Date
2023-09-26
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT04989283
Locations
🇺🇸

Community Medical Hospital, Missoula, Montana, United States

🇺🇸

The Mark H Zangmeister Center, Columbus, Ohio, United States

🇺🇸

Rush - Copley Medical Center, Aurora, Illinois, United States

and more 43 locations

Clinical Study on the Effectiveness and Safety Evaluation of Directional Atherectomy Combined With Drug-coated Balloons

First Posted Date
2021-08-02
Last Posted Date
2021-08-02
Lead Sponsor
Second Affiliated Hospital of Soochow University
Target Recruit Count
240
Registration Number
NCT04986098
Locations
🇨🇳

the Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

First Posted Date
2021-07-29
Last Posted Date
2022-04-27
Lead Sponsor
Akeso
Target Recruit Count
440
Registration Number
NCT04982237
Locations
🇨🇳

Women's Hospital School Of Medicine Zhejiang University, Hangzhou, China

🇨🇳

The Second Affiliated Hospital,Anhui Medical University, Hefei, China

🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, China

and more 2 locations

A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

First Posted Date
2021-07-29
Last Posted Date
2024-06-28
Lead Sponsor
Akeso
Target Recruit Count
138
Registration Number
NCT04982276
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, China

First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer

First Posted Date
2021-07-23
Last Posted Date
2021-10-01
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
172
Registration Number
NCT04974944
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer

First Posted Date
2021-07-22
Last Posted Date
2021-07-22
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
35
Registration Number
NCT04973904
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

Pembro+Chemo in Brain Mets

First Posted Date
2021-07-16
Last Posted Date
2024-10-21
Lead Sponsor
John L. Villano, MD, PhD
Target Recruit Count
3
Registration Number
NCT04964960
Locations
🇺🇸

University of Kentucky, Markey Cancer Center, Lexington, Kentucky, United States

Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer

First Posted Date
2021-07-12
Last Posted Date
2024-10-23
Lead Sponsor
Gilead Sciences
Target Recruit Count
92
Registration Number
NCT04958785
Locations
🇦🇺

St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia

🇺🇸

Charleston Oncology, Charleston, South Carolina, United States

🇦🇺

Peninsula Health, Frankston, Victoria, Australia

and more 39 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy